Express News | Renfu Pharmaceutical Group was approved to establish a national postdoctoral research workstation
Express News | Renfu Pharmaceutical: The controlling shareholder, Wuhan Contemporary Technology, was warned by the regulatory authorities to reduce its holdings in violation of regulations
Express News | Renfu Pharmaceutical: The controlling shareholder received the China Securities Regulatory Commission's decision on administrative supervision measures from the Hubei Regulatory Bureau
Humanwell Healthcare's Unit Gets FDA's Nod to Market Two Drugs
The US Food and Drug Administration approved the application of Humanwell Healthcare Group's (SHA:600079) unit, Epic Pharma, for two drugs, the company said in its filing on the Shanghai Stock Exchang
Humanwell Healthcare's Unit Gets Nod to Strengthen Oxycodone Hydrochloride Tablets' Dosage
Chinese drug regulator National Medical Products Administration approved the application of Yichang Humanwell Pharmaceutical, a unit of Humanwell Healthcare Group (SHA:600079), to increase the strengt
Express News | Renfu Pharmaceutical: Oxycodone hydrochloride extended-release tablets received a supplementary application approval notice
Express News | Renfu Pharmaceutical: The company's shares held by the controlling shareholder Contemporary Technology are pending freezing
Express News | Renfu Pharmaceutical: Net profit for the first quarter decreased by 26.89% year-on-year
Express News | Renfu Pharmaceutical: Fenofibrate tablets obtained US FDA approval number
Tianying Investment Group: Renfu Pharmaceutical Co., Ltd., the guarantor holder of corporate bonds, is pending freezing
Wuhan Tianying Investment Group Co., Ltd. announced that Renfu Pharmaceutical Group Co., Ltd. recently received a notification letter from the controlling shareholder Wuhan Contemporary Technology Industry Group Co., Ltd., and learned that the 16,867,255 shares of Renfu Pharmaceutical held by Contemporary Technology were pending freezing by the court on April 3. The frozen ratio accounted for 1.03% of Renfu Pharmaceutical's total share capital. As of April 3, 2024, all 386,767,393 shares of Contemporary Technology's holders have been judicially flagged and suspended, accounting for 100% of the total shares of Renfu Pharmaceutical and 23.69% of Renfu Pharmaceutical's total share capital.
Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Shares Lagging The Market But So Is The Business
When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 32x, you may consider Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) as a highly attractive investment w
Renfu Pharmaceutical (600079): Non-surgical departments are growing rapidly, and Yichang Renfu is moving forward steadily
Net profit after deducting non-return to mother grew rapidly. The company's total revenue in 2023 was 24.525 billion yuan (up 9.79% year on year), net profit not attributable to mother was 1,822 billion yuan (up 17.72% year on year), and net profit attributable to mother 21.
Express News | Renfu Pharmaceutical: Sodium divalproate extended-release tablets obtained a notice of approval for clinical trials of the drug
Express News | Renfu Pharmaceutical: Net profit in 2023 fell 14.07% year-on-year, and plans to pay 4.6 yuan for 10
Express News | Renfu Pharmaceutical: Phospropofol disodium for injection obtained approval notice for clinical trials of the drug
Could The Market Be Wrong About Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) Given Its Attractive Financial Prospects?
Humanwell Healthcare (Group)Ltd (SHSE:600079) has had a rough three months with its share price down 24%. However, stock prices are usually driven by a company's financial performance over the long
China Approves Sale of Humanwell Healthcare Unit's Prostate Cancer Treatment
China's medical products administrator granted Humanwell Healthcare Group (SHA:600079) unit Yichang Renfu Pharmaceutical a drug registration certificate for its enzalutamide soft capsules, according t
Yichang Renfu Products, a holding subsidiary of Renfu Pharmaceutical (600079.SH), obtained a drug registration certificate
Renfu Pharmaceutical (600079.SH) announced that the company's holding subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (abbreviated as “...
Express News | Renfu Pharmaceutical: Enzalutamide softgels obtained drug registration certificate
Humanwell Healthcare's Subsidiary Gets Nod to Register Idecalcidol Soft Capsules
Humanwell Healthcare Group's (SHA:600079) subsidiary, Humanwell PuraCap Pharmaceutical (Wuhan), received a drug registration certificate from China's National Medical Products Administration for its i
No Data